Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Generic Bimatoprost 0.01% vs Lumigan 0.01% in Glaucoma or Ocular Hypertension
NCT06267274Phase 1Recruiting
- Sponsor
- Amneal Pharmaceuticals, Inc.
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Amneal Pharmaceuticals, Inc. Primary endpoint: Intraocular Pressure at Day 42. Started Apr 2024; status: recruiting.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT06267274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06267274.